Cerus Corporation (NASDAQ: CERS) announced today that Hemakim, Cerus’ distributor for Turkey, has signed an agreement with the Florence Nightingale Hospital, a leading medical center in Turkey, to supply the INTERCEPT Blood System for platelets and plasma.
“With the adoption of the INTERCEPT Blood System, we know we are doing everything in our power to provide patients with safe and effective blood products, consistent with our mission to use innovative products to continuously improve patient care,” said Dr. Hulya Bilgen, associate professor and director of the Florence Nightingale Transfusion Center. “We strive to provide our patients and their families with the best the world can offer, with service from a qualified and experienced clinical staff.”
“We are extremely proud that the INTERCEPT system meets Florence Nightingale Hospital’s demanding standards for healthcare technologies, and we share the Hospital’s passion for patient safety,” said Caspar Hogeboom, president of Cerus Europe. “Including Turkey, customers in 18 countries have chosen the INTERCEPT Blood System to protect patients from transfusion-transmitted diseases.”
The Florence Nightingale Hospital Group, based in Istanbul, Turkey, offers patient-centered and specialized healthcare by integrating education, research and technology with clinical care. The group was founded in 1989, under the body of Turkish Cardiology Foundation, as the first cardiovascular disease hospital in the region. Today, with four general hospitals, a medical center, a teaching hospital, a clinical research center and a Hi-Tech hospital, the Florence Nightingale Hospital Group is one of the largest and most reputed hospitals in Europe and the Middle East.ABOUT CERUS Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV